Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement.

ABSTRACT: The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant number of the patients are on treatment with biologicals, and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a "cytokine storm" and associated organ damage characterized by an exaggerated release of pro-inflammatory type 1 and type 3 cytokines. These inflammatory responses are

SUBMITTER: Vultaggio A 

PROVIDER: S-EPMC7300800 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature